Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2014-12-01 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
高级管理人员辞职公告
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the resignation of a senior management personnel, specifically the Technical Quality Director. It includes statements from the board about the resignation and expresses gratitude for the individual's contributions. There is no financial data, report, or regulatory filing referenced beyond the management change. This fits the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board or senior management.
2014-12-01 Chinese
第八届董事会第十次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is an announcement of a board meeting resolution by the company 中源协和细胞基因工程股份有限公司. It details the approval of agreements related to issuance of shares and payment for asset purchases, including adjustments to share issuance price and quantity. The document includes voting results and mentions the involvement of related party transactions and director recusal. It is not a full financial report, audit, or earnings release, but rather a formal announcement of board decisions regarding capital/financing activities. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and contains substantive content about financing decisions, not just a notice or report publication announcement.
2014-11-27 Chinese
关于重大资产重组恢复审核的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from the company's board about the resumption of review of a major asset restructuring by the China Securities Regulatory Commission. It is brief (244 characters) and does not contain financial data or detailed report content. It is an announcement related to a regulatory process rather than a full report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2014-11-21 Chinese
2014年第八次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2014 eighth extraordinary general meeting of shareholders of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes the meeting agenda, rules, and detailed proposals to be voted on, such as the establishment of an internal accountability system and adjustment of idle funds cash management plan. It also includes voting procedures and legal opinions related to the meeting. The document is a meeting material packet for a shareholders meeting, not a report of voting results or a proxy solicitation. It is not a full annual or interim report, nor an earnings release or audit report. The content is consistent with materials shared during a shareholders meeting, which fits the definition of AGM Information (AGM-R). The document length is 3362 characters, which is relatively short but contains substantive meeting materials rather than just an announcement or notice. Therefore, the best classification is AGM Information (AGM-R).
2014-11-20 Chinese
关于调整闲置资金现金管理计划的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of 中源协和细胞基因工程股份有限公司 regarding the adjustment of the company's idle funds cash management plan. It details the investment scope, risk control measures, and the approval process by the board and shareholders. The document does not contain financial statements or detailed financial data but rather informs shareholders and the public about a corporate decision related to cash management and investment strategy. It is not a full financial report, earnings release, or regulatory certification. Given the nature of the content as an official announcement about a financing/capital management plan, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on the update of cash management plans, fitting the CAP category with high confidence.
2014-11-14 Chinese
证券投资管理制度
Governance Information Classification · 95% confidence The document is titled '证券投资管理制度' which translates to 'Securities Investment Management System'. It outlines internal policies and procedures for managing securities investments by the company, including principles, account management, risk control, and responsibilities. There is no indication that this is a financial report, audit, earnings release, or any regulatory filing announcing results or changes. It is a governance or internal control document related to investment management policies. It does not fit into categories like Annual Report, Interim Report, or Regulatory Filings. The closest specific category is Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices. The document is about internal governance of securities investment, so CGR is the best fit. The document length is 3200 characters, which is not extremely short, and it is a full policy document, not an announcement or certification. Therefore, the classification is Governance Information (CGR) with high confidence.
2014-11-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.